Thirty-five state and regional hospital associations today urged the U.S. Court of Appeals for the District of Columbia Circuit to reverse a district court decision and grant a preliminary injunction to stop a nearly 30% Medicare payment reduction for many hospitals in the 340B Drug Pricing Program while the AHA and other hospital groups challenge the payment cut on appeal. “In evaluating the district court’s denial of a preliminary injunction, this Court must consider the extent to which an injunction is necessary to avert irreparable harm, the balance of the equities, and whether an injunction will serve the public interest,” the associations said in a friend-of-the-court brief. “It is difficult to imagine a case that more obviously satisfies those criteria. The new [Centers for Medicare & Medicaid Services] rule will hobble the ability of hospitals throughout the United States to provide health care to vulnerable populations and, in turn, will jeopardize the lives and health of countless needy patients. For these reasons, amici respectfully urge the Court to reverse the District Court’s decision.”

Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The AHA and dozens of other organizations April 14 sent a letter of support to Reps. Suzan DelBene, D-Wash., and Mike Kelly, R-Pa., for their introduction…
Headline
The Medicare Payment Advisory Commission met April 9 and 10 to discuss several topics, including the relationship between Medicare Advantage enrollment and…
Headline
The Centers for Medicare & Medicaid Services issued an updated registration link for its webinar April 16 at 3 p.m. ET on Medicare Clinical…
Perspective
Public
Few patient populations are more vulnerable to the shifting winds around health care today than Medicare beneficiaries who need specialized, high-acuity and…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…